Modern Pathology:癌细胞、基质和腔隙组织差异与前列腺癌MRI体内检测能力相关

2019-06-23 AlexYang MedSci原创

最近,有研究人员调查了可能影响前列腺癌多重参数核磁共振成像(MP-MRI)检测能力的组织病理学因素。他们的回顾性研究包括了59名连续性的患者,这些经历了MP-MRI并随后经历个根治性前列腺切除术。这些案例在最后病理学诊断中根据肿瘤大小(10毫米到20毫米)进行了标准化。研究发现,在59个前列腺切除样本中,没有案例具有与大小标准匹配的2个或者以上的癌症病灶位点。在59个病灶部位,35个为MRI可检测

最近,有研究人员调查了可能影响前列腺癌多重参数核磁共振成像(MP-MRI)检测能力的组织病理学因素。

他们的回顾性研究包括了59名连续性的患者,这些经历了MP-MRI并随后经历个根治性前列腺切除术。这些案例在最后病理学诊断中根据肿瘤大小(10毫米到20毫米)进行了标准化。研究发现,在59个前列腺切除样本中,没有案例具有与大小标准匹配的2个或者以上的癌症病灶位点。在59个病灶部位,35个为MRI可检测的(前列腺成像报告和数据系统(PIRADS)得分3分或以上),而24个为MRI不可检测的(PRIRADS得分2分或者更少)。研究人员在MRI可检测组和不可检测组中,在格林森等级分组、格林森模式4比例和格林森模式4优势亚型中没有发现显著差异。从另一方面来讲,与MRI不可检测癌症相比,MRI可检测癌症中癌症细胞平均面积分数显著更高(60.9% vs. 42.7%, P<0.0001),基质平均面积分数(33.8% vs. 45.1%, P=0.00089)和腔体积更低(5.2% vs. 12.2%, P<0.0001)。多变量分析中,癌细胞面积(P=0.0031)和腔体积(P=0.0035)分别表现出了与MRI可检测性强烈的正相关和负相关关系。

最后,研究人员指出,癌症细胞、基质和腔体积的变化,应该考虑作为前列腺癌MRI临床和体内可检测性最好的预测因子之一,而不是传统的组织学参数。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786287, encodeId=edf61e86287e2, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Nov 18 18:26:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252612, encodeId=b23d12526126b, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Jun 25 04:26:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368239, encodeId=b7e8368239f2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Jun 24 05:58:57 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757183, encodeId=bddf1e5718352, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Apr 14 11:26:00 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040482, encodeId=cde310404827b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 23 16:26:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]
    2019-11-18 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786287, encodeId=edf61e86287e2, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Nov 18 18:26:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252612, encodeId=b23d12526126b, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Jun 25 04:26:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368239, encodeId=b7e8368239f2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Jun 24 05:58:57 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757183, encodeId=bddf1e5718352, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Apr 14 11:26:00 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040482, encodeId=cde310404827b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 23 16:26:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]
    2019-06-25 yxch36
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786287, encodeId=edf61e86287e2, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Nov 18 18:26:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252612, encodeId=b23d12526126b, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Jun 25 04:26:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368239, encodeId=b7e8368239f2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Jun 24 05:58:57 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757183, encodeId=bddf1e5718352, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Apr 14 11:26:00 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040482, encodeId=cde310404827b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 23 16:26:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]
    2019-06-24 njwbhuang

    好文章!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1786287, encodeId=edf61e86287e2, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Nov 18 18:26:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252612, encodeId=b23d12526126b, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Jun 25 04:26:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368239, encodeId=b7e8368239f2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Jun 24 05:58:57 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757183, encodeId=bddf1e5718352, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Apr 14 11:26:00 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040482, encodeId=cde310404827b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 23 16:26:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1786287, encodeId=edf61e86287e2, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Nov 18 18:26:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252612, encodeId=b23d12526126b, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Jun 25 04:26:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368239, encodeId=b7e8368239f2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Mon Jun 24 05:58:57 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757183, encodeId=bddf1e5718352, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Apr 14 11:26:00 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040482, encodeId=cde310404827b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 23 16:26:00 CST 2019, time=2019-06-23, status=1, ipAttribution=)]
    2019-06-23 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

盘点:前列癌研究进展

前列腺是男性生殖器附属腺中最大的实质性器官。由前列腺组织和肌组织构成。前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常我们所说的前列腺癌就是指前列腺腺癌。梅斯医学小编整理了近期前列腺癌的研究进展,与大家一起分享学习!【1

Sci Rep:前列腺癌中ETS转录因子ETV1和TGF-β调控的SMAD蛋白关系研究

ETS转录因子ETV1在恶性前列腺癌中经常过表达,也是前列腺癌的病因之一。相应地,前列腺特异性过表达ETV1的转基因小鼠能够发生前列腺上皮内瘤样病变。然而,这些小鼠中却并不能发展为恶性肿瘤阶段,表明了抑制途径可能阻止了ETV1的完整致瘤作用。最近,有研究人员表明了TGF-β/SMAD信号就是上述的抑制途径。首先,研究人员发现ETV1能够与SMAD4形成复合物。其次,SMAD2、SMAD3和SMAD

2019 FROGG建议:淋巴结阳性前列腺癌的放射治疗

2019年6月,澳大利亚和新西兰泌尿生殖肿瘤放疗小组(FROGG)发布了淋巴结阳性前列腺癌的放射治疗建议,淋巴结阳性前列腺癌的治疗包括局部治疗和系统治疗。本文主要针对淋巴结阳性前列腺癌的放射治疗提出指导建议,内容涉及成像技术,放射治疗靶标和剂量以及雄激素剥夺疗法的应用。

PSA升高,就得了前列腺癌?

目前,在男性体检筛查中有一项重要的检查就是PSA指标。经常有人在拿到自己的体检报告的时候会有这样的疑问:tPSA和fPSA分别是什么?我的结果值高是不是就是得了前列腺癌?这fPSA/tPSA比值有啥意义? tPSA是总前列腺特异性抗原,由前列腺上皮细胞合成分泌至精液中,它只存在于人前列腺细胞中,不表达于其它细胞。正常的前列腺导管系统周围存在着屏障,避免了前列腺上皮产生的PSA直接进入血液之中

Radiology:压缩感知MRI前列腺灌注在前列腺癌诊断的价值

本研究旨在探究基于VIBE或GRASP动态增强对比(DCE)MRI序列联合扩散加权成像(DWI)与传统单参数DWI的诊断效能。

Eur J Cancer Care (Engl):去势难治性前列腺癌骨转移患者中心理压力与疼痛减轻没有相关性

驱使难治性前列腺癌(CRPC)患者中,骨转移疼痛能够引起生活质量的降低(QoL)。在具有骨转移症状的CRPC患者中,镭-223治疗与良好的生存益处和骨疼痛显著减轻相关。最近,有研究人员评估了镭-223治疗期间,疼痛减轻与心理压力之间的相关性。研究总共包括了63名具有mCRPC的患者,他们均经历了镭-223治疗,并且对他们详细的说明了改善疼痛和增加生存的可能性。研究人员利用简要疼痛量表数值评定量表对